Want to join the conversation?
Diversified pharma & health care products company $ABT expects 1Q16 EPS, excluding specified items, in the range of $0.38-0.40. Full-year GAAP EPS guidance range of $1.55-1.65 & adjusted EPS of $2.10-2.20. FY16 forecast assumes significantly lower contribution from Venezuelan operations as a result of challenging market conditions in that country.
No better outlook on $MSFT. Even if the results beat a bit, the stock may move 4 to 6% higher, but won't go above $60.